Reset filter
Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

42 Search results.
Relevance Rating New first Old first

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Concomitant Medications, Asthma Exacerbations, IP Device Malfunction, Chest X-Ray, Pharmacogenetic Research Consent/ Sample Collection, Investigational Product Compliance and Unsceduled Asthma related Healthcare Resource Utilisation - Subject Logs

- 11/17/18 - 1 form, 9 itemgroups, 81 items, 1 language
Itemgroups: Concomitant Medication, Asthma Exacerbations, Contact Method/ Treatment site for ExacerbationsMethod, Exacerbation Medications, IP Device Malfunction, Chest X-Ray, Pharmacogenetic (PGx) Research Consent/ Sample Collection, Investigational Product Compliance, Unscheduled Asthma related Healthcare Resource Utilisation
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Eligibility Carcinoma, Non-Small-Cell Lung NCT01261299

- 10/28/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01261299

Eligibility Lung Neoplasm NCT00469066

- 8/6/17 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cone Beam CT Scanning in Lung and Bladder Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT00469066

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Medical Conditions, Family History, Disease Duration, Vital Signs, Candidiasis Examination, Electronically Transferred Lab Data - Screening

- 11/21/18 - 1 form, 11 itemgroups, 34 items, 1 language
Itemgroups: Medical Conditions - Cardiac Disorders, Medical Conditions - Endocrine Disorders, Medical Conditions - Eye Disorders, Medical Conditions - Vascular Disorders, Medical Conditions - Metabolism and Nutrition Disorders, Medical Conditions - Infections and Infestations, Family History, Disease Duration, Vital Signs, Candidiasis Examination, Electronically transferred lab data
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Eligibility Stage III Non-small Cell Lung Cancer NCT02076282

- 7/10/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
MRI Optimization Study in Stage III NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02076282

Eligibility Recurrent Non-small Cell Lung Cancer NCT02059889

- 6/27/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02059889

Eligibility Lung Cancer NCT00955695

- 7/7/20 - 1 form, 1 itemgroup, 20 items, 1 language
Itemgroup: Criteria
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00955695

Eligibility Lung Cancer NCT01514877

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01514877

Eligibility Non-Small Cell Lung Cancer NCT00667082

- 7/21/18 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00667082

Eligibility Non Small Cell Lung Cancer NCT00415363

- 5/18/17 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00415363

Eligibility Lung Cancer, Non-Small Cell NCT00390806

- 4/23/17 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00390806

Eligibility Lung Cancer NCT00403065

- 4/23/17 - 1 form, 1 itemgroup, 13 items, 1 language
Itemgroup: Criteria
Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery; ODM derived from: https://clinicaltrials.gov/show/NCT00403065

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial